
Roy Strowd III MD MEd, MS
Neurooncology
Associate Professor Department of Neurology Department of Internal Medicine, Section on Hematology and Oncology Department of Clinical and Translational Sciences
Join to View Full Profile
Medical Center BlvdWinston Salem, NC 27157
Phone+1 336-716-7548
Dr. Strowd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Roy Strowd is a neurologist and Neuro-Oncologist in Winston Salem, NC and is affiliated with Wake Forest Baptist Medical Center. He received his medical degree from Wake Forest School of Medicine, fellowship training at Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center and has been in practice 4 years. He specializes in neuro-oncology and is experienced in treating patients with primary brain tumors, cancer syndromes like neurofibromatosis, tuberous sclerosis, and neurological complications of cancer.
Education & Training
- Johns Hopkins School of EducationMEd, Health Professions Education, 2014 - 2018
- Johns Hopkins UniversityFellowship, Neuro-Oncology, 2013 - 2015
- Wake Forest University Baptist Medical CenterChief Residency, Neurology, 2012 - 2013
- Wake Forest University Baptist Medical CenterResidency, Neurology, 2009 - 2013
- Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2009
Certifications & Licensure
- NC State Medical License 2009 - 2025
- MD State Medical License 2013 - 2015
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors Start of enrollment: 2016 May 01
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Start of enrollment: 2018 Jul 09
- Join now to see all
Publications & Presentations
PubMed
- A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.Patrick Y Wen, Andrea Manzanera, Caroline Duault, Edgar Gonzalez-Kozlova, Lenika Lopez
Neuro-Oncology. 2025-03-22 - Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.Yang Yu, Austin Arrigo, Ankush Chandra, Chuling Zhuang, Mariana K Najjar
Biorxiv. 2025-02-26 - A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.Veronica Rendo, Eudocia Q Lee, Connor Bossi, Nicholas Khuu, Michelle A Rudek
Science Translational Medicine. 2025-02-19
Press Mentions
- How Does the Body Feel Pain? | Neuropathic PainFebruary 12th, 2023
- Opioid Stewardship Training Empowers Medical Students to Address Addiction and Pain ManagementDecember 15th, 2021
- One Major Effect the Keto Diet Has on Cancer, New Study SuggestsJuly 17th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: